- •Current guidelines suggested a dosage up to 600 units (U) of botulinum toxin type A (BoNT-A) in post-stroke spasticity
- •High doses of incobotulinumtoxinA (840U) showed efficacy and safety in severe post-stroke upper and lower limb spasticity
- •In a 2-year follow-up on 20 patients, a reduction of spasticity/disability was found with repeated high doses of incobotulinumtoxinA
- •One month after the last BoNT-A administration, the efficacy on spasticity/disability was similar to that at baseline
- •Long-term treatment with high doses of incobotulinumtoxinA was safe and effective in post-stroke upper and lower limb spasticity
Current guidelines suggested a dosage up to 600 units (U) of botulinum toxin type A (BoNT-A) (onabotulinumtoxinA or incobotulinumtoxinA) in reducing spastic hypertonia with low prevalence of complications, although a growing body of evidence showed efficacy with the use of high doses (>800 U). The available evidence mainly referred to a single set of injections evaluating the efficacy and safety of the neurotoxin 30 days after the treatment. In a prospective, non-randomized, open-label study, we studied the safety of repeated higher doses of incobotulinumtoxinA in post-stroke upper and lower limb spasticity.
Two years after the first set of injections, we evaluated in 20 stroke survivors with upper and lower limb spasticity the long-term safety of repeated high doses of incobotulinumtoxinA (up to 840 U) for a total of eight sets of injections.
Patients reported an improvement of their clinical picture concerning a reduction of spasticity measured with the Asworth Scale (AS) for elbow, wrist, fingers and ankle flexor muscles and disability measured with the Disability Assessment Scale (DAS) 30 days after the last set of injections (eighth set) compared to the baseline (p < 0.0001). No difference in AS and DAS scores has been found between t1 (30 days after the first injection set) and t2 (30 days after the eighth set of injections), with also similar safety.
In a two-year follow-up, repeated high doses of incobotulinumtoxinA, administered for eight sets of injections, appeared to be safe in patients with upper and lower limb spasticity after stroke without general adverse effects.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Xeomin is free from complexing proteins.Toxicon. 2009; 54: 697-701https://doi.org/10.1016/j.toxicon.2009.03.010
- Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?.Biologics. 2010; 4: 325-332https://doi.org/10.2147/BTT.S14902
- Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.J. Neural Transm. 2013; 120: 469-476https://doi.org/10.1007/s00702-012-0892-x
- High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy.NeuroRehabilitation. 2014; 34: 515-522https://doi.org/10.3233/NRE-141052
- Safety aspects of incobotulinumtoxinA high-dose therapy.J. Neural Transm. 2015; 122: 327-333https://doi.org/10.1007/s00702-014-1252-9
- European consensus table on the use of botulinum toxin type A in adult spasticity.J. Rehabil. Med. 2009; 41: 13-25https://doi.org/10.2340/16501977-0303
- Preliminary trial of carisoprodol in multiple sclerosis.Practitioner. 1964; 192: 540-542
- Inter- and intra-rater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity.Arch. Phys. Med. Rehabil. 2002; 83: 1349-1354https://doi.org/10.1053/apmr.2002.35474
- Management of spasticity associated pain with botulinum toxin A.J. Pain Symptom Manag. 2000; 20: 44-49https://doi.org/10.1016/S0885-3924(00)00146-9
- Efficacy and safety of NT 201 for upper limb spasticity of various etiologies—a randomized parallel-group study.Acta Neurol. Scand. 2010; 122: 295-302https://doi.org/10.1111/j.1600-0404.2010.01354.x
- Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.J. Rehabil. Med. 2011; 43: 486-492https://doi.org/10.2340/16501977-0796
- Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity.Muscle Nerve. 2016; 53: 415-421https://doi.org/10.1002/mus.24776
- Treatment of upper limb spasticity after stroke: one-year safety and ef cacy of botulinum toxin type A NT201.Int. J. Immunopathol. Pharmacol. 2012; 25: 57S-62S
- Botulinum toxin therapy: risk factors for therapy failure.Mov. Disord. 2000; 15: 51
- Development of resistance to botulinum toxin type A in patients with torticollis.Mov. Disord. 1994; 9: 213-217https://doi.org/10.1002/mds.870090216
- Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.Eur. J. Neurol. 2006; 13: 11-15https://doi.org/10.1111/j.1468-1331.2006.01439.x
- Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia.Drugs. 2007; 67: 669-683
- Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases.J. Neurol. Neurosurg. Psychiatry. 1997; 62: 198
Merz Pharmaceuticals GmbH. Xeomin® US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125360s045lbl.pdf. (accessed January 10, 2017).
- Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques.J. Neurol. Sci. 2014; 347: 39-43
- Post-stroke spasticity as a condition: a new perspective on patient evaluation.Funct. Neurol. 2016; 31: 179-180https://doi.org/10.2340/16501977-2231
- Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.Neurotoxicology. 2005; 26: 785-793https://doi.org/10.1016/j.neuro.2005.01.017
Published online: May 01, 2017
Accepted: April 30, 2017
Received in revised form: April 11, 2017
Received: January 21, 2017
© 2017 Elsevier B.V. All rights reserved.